Dalbavancin vs linezolid for treatment of acute bacterial infections of the skin.

Trial Profile

Dalbavancin vs linezolid for treatment of acute bacterial infections of the skin.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Dalbavancin (Primary) ; Linezolid
  • Indications Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Vicuron Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2017 Results of retrospective analysis presented at the ASM Microbe 2017
    • 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data from four phase III studies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 30 Oct 2016 Pooled results of this and other 3 trial (DUR001-301, DUR001-302 and DUR001-303) presented at the IDWeek 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top